Literature DB >> 27645292

[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration.

Keith A Josephs1, Jennifer L Whitwell2, Pawel Tacik3, Joseph R Duffy4, Matthew L Senjem5, Nirubol Tosakulwong6, Clifford R Jack2, Val Lowe2, Dennis W Dickson3, Melissa E Murray3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27645292      PMCID： PMC5107140          DOI： 10.1007/s00401-016-1618-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  9 in total

1.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Authors:  David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

2.  Office of Rare Diseases neuropathologic criteria for corticobasal degeneration.

Authors:  D W Dickson; C Bergeron; S S Chin; C Duyckaerts; D Horoupian; K Ikeda; K Jellinger; P L Lantos; C F Lippa; S S Mirra; M Tabaton; J P Vonsattel; K Wakabayashi; I Litvan
Journal:  J Neuropathol Exp Neurol       Date:  2002-11       Impact factor: 3.685

3.  Beta-amyloid burden is not associated with rates of brain atrophy.

Authors:  Keith A Josephs; Jennifer L Whitwell; Zeshan Ahmed; Maria M Shiung; Stephen D Weigand; David S Knopman; Bradley F Boeve; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson; Clifford R Jack
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422

4.  Criteria for the diagnosis of corticobasal degeneration.

Authors:  Melissa J Armstrong; Irene Litvan; Anthony E Lang; Thomas H Bak; Kailash P Bhatia; Barbara Borroni; Adam L Boxer; Dennis W Dickson; Murray Grossman; Mark Hallett; Keith A Josephs; Andrew Kertesz; Suzee E Lee; Bruce L Miller; Stephen G Reich; David E Riley; Eduardo Tolosa; Alexander I Tröster; Marie Vidailhet; William J Weiner
Journal:  Neurology       Date:  2013-01-29       Impact factor: 9.910

5.  Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.

Authors:  Marta Marquié; Marc D Normandin; Charles R Vanderburg; Isabel M Costantino; Elizabeth A Bien; Lisa G Rycyna; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik L Debnath; Neil Vasdev; Bradford C Dickerson; Stephen N Gomperts; John H Growdon; Keith A Johnson; Matthew P Frosch; Bradley T Hyman; Teresa Gómez-Isla
Journal:  Ann Neurol       Date:  2015-09-25       Impact factor: 10.422

6.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.

Authors:  Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad
Journal:  Alzheimers Dement       Date:  2016-02-15       Impact factor: 21.566

7.  Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Ankit V Master; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Brain       Date:  2012-03-01       Impact factor: 13.501

8.  18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.

Authors:  Ruben Smith; Andreas Puschmann; Michael Schöll; Tomas Ohlsson; John van Swieten; Michael Honer; Elisabet Englund; Oskar Hansson
Journal:  Brain       Date:  2016-06-29       Impact factor: 13.501

9.  An autoradiographic evaluation of AV-1451 Tau PET in dementia.

Authors:  Val J Lowe; Geoffry Curran; Ping Fang; Amanda M Liesinger; Keith A Josephs; Joseph E Parisi; Kejal Kantarci; Bradley F Boeve; Mukesh K Pandey; Tyler Bruinsma; David S Knopman; David T Jones; Leonard Petrucelli; Casey N Cook; Neill R Graff-Radford; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Melissa E Murray
Journal:  Acta Neuropathol Commun       Date:  2016-06-13       Impact factor: 7.801
  9 in total
  67 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

Review 2.  Future Directions in Imaging Neurodegeneration.

Authors:  Joseph C Masdeu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

3.  Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration.

Authors:  Katerina A Tetzloff; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Sarah M Boland; Rene L Utianski; Hugo Botha; Matthew L Senjem; Christopher G Schwarz; Keith A Josephs; Jennifer L Whitwell
Journal:  Neurocase       Date:  2018-05-25       Impact factor: 0.881

4.  18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome.

Authors:  Anna E Goodheart; Joseph J Locascio; Wesley R Samore; Jessica A Collins; Michael Brickhouse; Aaron Schultz; Alexandra Touroutoglou; Keith A Johnson; Matthew P Frosch; John H Growdon; Bradford C Dickerson; Stephen N Gomperts
Journal:  Brain       Date:  2021-02-12       Impact factor: 13.501

5.  Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration.

Authors:  Corey T McMillan; David J Irwin; Ilya Nasrallah; Jeffrey S Phillips; Meredith Spindler; Katya Rascovsky; Kylie Ternes; Charles Jester; David A Wolk; Linda K Kwong; Virginia M-Y Lee; Edward B Lee; John Q Trojanowski; Murray Grossman
Journal:  Acta Neuropathol       Date:  2016-11-04       Impact factor: 17.088

6.  [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation.

Authors:  F Ali; J L Whitwell; P R Martin; M L Senjem; D S Knopman; C R Jack; V J Lowe; R C Petersen; B F Boeve; K A Josephs
Journal:  J Neurol       Date:  2018-03-01       Impact factor: 4.849

7.  Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.

Authors:  Joseph R Winer; Anne Maass; Peter Pressman; Jordan Stiver; Daniel R Schonhaut; Suzanne L Baker; Joel Kramer; Gil D Rabinovici; William J Jagust
Journal:  JAMA Neurol       Date:  2018-02-01       Impact factor: 18.302

8.  Prosodic and phonetic subtypes of primary progressive apraxia of speech.

Authors:  Rene L Utianski; Joseph R Duffy; Heather M Clark; Edythe A Strand; Hugo Botha; Christopher G Schwarz; Mary M Machulda; Matthew L Senjem; Anthony J Spychalla; Clifford R Jack; Ronald C Petersen; Val J Lowe; Jennifer L Whitwell; Keith A Josephs
Journal:  Brain Lang       Date:  2018-07-04       Impact factor: 2.381

9.  Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.

Authors:  Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell
Journal:  Ann Neurol       Date:  2020-09-12       Impact factor: 10.422

10.  FDG-PET patterns associated with underlying pathology in corticobasal syndrome.

Authors:  Matteo Pardini; Edward D Huey; Salvatore Spina; William C Kreisl; Silvia Morbelli; Eric M Wassermann; Flavio Nobili; Bernardino Ghetti; Jordan Grafman
Journal:  Neurology       Date:  2019-01-30       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.